A mitotically active, cellular tumor stroma and/or inflammatory cells associated with tumor cells may contribute to intermediate or high Oncotype DX Recurrence Scores in low-grade invasive breast carcinomas

Modern Pathology

Volumn 25, Issue 4, 2012, Pages 556-566

  Acs, Geza ^a,b,c   Esposito, Nicole N ^a,b   Kiluk, John ^a   Loftus, Loretta ^a   Laronga, Christine ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

^c Ruffolo Hooper and Associates   (United States)

Author keywords

breast carcinoma; cell proliferation; Ki 67; oncotype DX; recurrence Score; tumor stroma

Indexed keywords

CYTOKERATIN; KI 67 ANTIGEN; PROGESTERONE RECEPTOR;

ADULT; AREA UNDER THE CURVE; ARTICLE; ASSAY; BREAST CARCINOMA; CANCER GRADING; CANCER RECURRENCE; CANCER RISK; CARCINOMA CELL; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; INFLAMMATORY CELL; INVASIVE CARCINOMA; MAJOR CLINICAL STUDY; MITOSIS RATE; MUCINOUS CARCINOMA; ONCOTYPE DX RECURRENCE SCORE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RECEIVER OPERATING CHARACTERISTIC; STROMA CELL; TUMOR CELL;

ADENOCARCINOMA; ADENOCARCINOMA, MUCINOUS; BREAST NEOPLASMS; CHI-SQUARE DISTRIBUTION; FEMALE; FLORIDA; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC TESTING; HUMANS; IMMUNOHISTOCHEMISTRY; INFLAMMATORY BREAST NEOPLASMS; MIDDLE AGED; MITOSIS; NEOPLASM GRADING; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS; STROMAL CELLS; TUMOR MARKERS, BIOLOGICAL; TUMOR MICROENVIRONMENT;

EID: 84859434967     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2011.194     Document Type: Article

References (74)

1. Simpson PT, Reis-Filho JS, Gale T, et al. Molecular evolution of breast cancer. J Pathol 2005;205:248-254.
2. Weigelt B, Reis-Filho JS. Histological and molecular types of breast cancer: is there a unifying taxonomy? Nat Rev Clin Oncol 2009;6:718-730.
3. Weigelt B, Baehner FL, Reis-Filho JS. The contribution of gene expression profiling to breast cancer classification, prognostication and prediction: a retrospective of the last decade. J Pathol 2010;220:263-280.
4. Azzopardi JG, Ahmed A, Millis RR. Problems in Breast Pathology. WB Saunders: London, 1979.
5. Page DL, Anderson TJ. Diagnostic Histopathology of the Breast. Churchill Livingstone: Edinburgh, 1987.
6. Tavassoli FA. Pathology of the Breast. Appleton & Lange: Stamford, 1999.
7. Rosen PP, Oberman HA. Tumors of theMammary Gland. Armed Forces Institute of Pathology: Washington, DC, 1993.
8. Rosen PP. Rosen's Breast Pathology. Williams & Wilkins: Philadelphia, 2001.
9. Elston CW, Ellis IO. Assessment of histologic grade In: Elston CW, Ellis IO (eds). The Breast 3rd edn. Churchill Livingstone: Edinburgh, 1998, pp 365-384.
10. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with longterm follow-up. Histopathology 2002;41:154-161.
11. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with longterm follow-up. Histopathology 1991;19:403-410.
12. Sundquist M, Thorstenson S, Brudin L, et al. Applying the Nottingham Prognostic Index to a Swedish breast cancer population. South East Swedish Breast Cancer Study Group. Breast Cancer Res Treat 1999;53:1-8. (Pubitemid 29123614)
13. Saimura M, Fukutomi T, Tsuda H, et al. Prognosis of a series of 763 consecutive node-negative invasive breast cancer patients without adjuvant therapy: analysis of clinicopathological prognostic factor. J Surg Oncol 1999;71:101-105. (Pubitemid 29288487)
14. Rakha EA, Reis-Filho JS, Baehner F, et al. Breast cancer prognostic classification in the molecular era: the role of histological grade. Breast Cancer Res 2010;12:207.
15. Lundin J, LundinM, Holli K, et al. Omission of histologic grading from clinical decision making may result in overuse of adjuvant therapies in breast cancer: results from a nationwide study. J Clin Oncol 2001;19:28-36. (Pubitemid 32063476)
16. Simpson JF, Gray R, Dressler LG, et al. Prognostic value of histologic grade and proliferative activity in axillary node-positive breast cancer: results from the Eastern Cooperative Oncology Group Companion Study, EST 4189. J Clin Oncol 2000;18:2059-2069. (Pubitemid 30324359)
17. Frkovic-Grazio S, Bracko M. Long term prognostic value of Nottingham histological grade and its components in early (pT1N0M0) breast carcinoma. J Clin Pathol 2002;55:88-92. (Pubitemid 34123906)
18. Anderson TJ, Alexander FE, Lamb J, et al. Pathology characteristics that optimize outcome prediction of a breast screening trial. Br J Cancer 2000;83:487-492. (Pubitemid 30487862)
19. Blamey RW, Hornmark-Stenstam B, Ball G, et al. ONCOPOOL-a European database for 16 944 cases of breast cancer. Eur J Cancer 2010;46:56-71.
20. Mirza AN, Mirza NQ, Vlastos G, et al. Prognostic factors in node-negative breast cancer: a review of studies with sample size more than 200 and follow-up more than 5 years. Ann Surg 2002;235:10-26. (Pubitemid 34062395)
21. Warwick J, Tabar L, Vitak B, et al. Time-dependent effects on survival in breast carcinoma: results of 20 years of follow-up from the Swedish Two-County Study. Cancer 2004;100:1331-1336. (Pubitemid 38366834)
22. Blamey RW, Ellis IO, Pinder SE, et al. Survival of invasive breast cancer according to the Nottingham Prognostic Index in cases diagnosed in 1990-1999. Eur J Cancer 2007;43:1548-1555. (Pubitemid 46901016)
23. Haybittle JL, Blamey RW, Elston CW, et al. A prognostic index in primary breast cancer. Br J Cancer 1982;45:361-366. (Pubitemid 12122304)
24. Todd JH, Dowle C, Williams MR, et al. Confirmation of a prognostic index in primary breast cancer. Br J Cancer 1987;56:489-492. (Pubitemid 17146357)
25. Goldhirsch A, Ingle JN, Gelber RD, et al. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol 2009;20:1319-1329.
26. Page DL, Simpson JF. Pathology of preinvasive and excellent-prognosis breast cancer. Curr Opin Oncol 2000;12:526-531. (Pubitemid 32039651)
27. Page DL, Anderson TJ, Sakamoto G. Infiltrating carcinoma: Major histologic types. In: Page DL, Anderson TJ (eds). Diagnostic Histopathology of the Breast. WB Saunders: London, 1987, pp 193-235.
28. Simpson JF, Page DL. Pathology of preinvasive and excellent prognosis breast cancer. Curr Opin Oncol 2001;13:426-430. (Pubitemid 33027893)
29. Rakha EA, El-Sayed ME, Lee AH, et al. Prognostic significance of Nottingham histologic grade in invasive breast carcinoma. J Clin Oncol 2008;26:3153-3158.
30. Acs G. Invasive carcinoma, special types In: Lawton TJ (ed) Breast Cambridge Illustrated Surgical Pathology. Cambridge University Press: Cambridge, 2009, pp 137-184.
31. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004;351:2817-2826. (Pubitemid 40051905)
32. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature 2000; 406:747-752.
33. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001;98:10869-10874. (Pubitemid 32878711)
34. Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 2003;100:8418-8423. (Pubitemid 36842560)
35. van de Vijver MJ, He YD, Van't Veer LJ, et al. A geneexpression signature as a predictor of survival in breast cancer. N Engl J Med 2002;347:1999-2009. (Pubitemid 35461656)
36. Sotiriou C, Wirapati P, Loi S, et al. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 2006;98:262-272. (Pubitemid 43264710)
37. Wang Y, Klijn JG, Zhang Y, et al. Gene-expression profiles to predict distant metastasis of lymph-nodenegative primary breast cancer. Lancet 2005;365: 671-679. (Pubitemid 40260888)
38. Potti A, Dressman HK, Bild A, et al. Genomic signatures to guide the use of chemotherapeutics. Nat Med 2006;12:1294-1300. (Pubitemid 44706932)
39. Habel LA, Shak S, Jacobs MK, et al. A populationbased study of tumor gene expression and risk of breast cancer death among lymph node-negative patients. Breast Cancer Res 2006;8:R25.
40. Esteva FJ, Sahin AA, Cristofanilli M, et al. Prognostic role of a multigene reverse transcriptase-PCR assay in patients with node-negative breast cancer not receiving adjuvant systemic therapy. Clin Cancer Res 2005;11:3315-3319. (Pubitemid 40627881)
41. Gianni L, Zambetti M, Clark K, et al. Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. J Clin Oncol 2005; 23:7265-7277. (Pubitemid 46202341)
42. Paik S, Tang G, Shak S, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 2006;24:3726-3734. (Pubitemid 46622311)
43. Harris L, Fritsche H, Mennel R, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007;25:5287-5312. (Pubitemid 350232263)
44. Allison KH, Kandalaft PL, Sitlani CM, Dintzis SM, Gown AM. Routine pathologic parameters can predict Oncotype DX(TM) recurrence scores in subsets of ER positive patients: who does not always need testing? Breast Cancer Res Treat 2011, E-pub ahead of print.
45. Baehner F, Quale C, Pomeroy C, et al. Biopsy cavities in breast cancer specimens: their impact on quantitative RT-PCR gene expression profiles and recurrence risk assessment (abstract). Mod Pathol 2008;22: 28A-29A.
46. Diab SG, Clark GM, Osborne CK, et al. Tumor characteristics and clinical outcome of tubular and mucinous breast carcinomas. J Clin Oncol 1999; 17:1442-1448. (Pubitemid 29220850)
47. Page DL, Dixon JM, Anderson TJ, et al. Invasive cribriform carcinoma of the breast. Histopathology 1983;7:525-536. (Pubitemid 13069410)
48. Venable JG, Schwartz AM, Silverberg SG. Infiltrating cribriform carcinoma of the breast: a distinctive clinicopathologic entity. Hum Pathol 1990;21:333-338. (Pubitemid 20081235)
49. Rakha EA, Lee AH, Evans AJ, et al. Tubular carcinoma of the breast: further evidence to support its excellent prognosis. J Clin Oncol 2010;28:99-104.
50. Javid SH, Smith BL, Mayer E, et al. Tubular carcinoma of the breast: results of a large contemporary series. Am J Surg 2009;197:674-677.
51. Hanagiri T, Ono K, Baba T, et al. Clinicopathologic characteristics of mucinous carcinoma of the breast. Int Surg 2010;95:126-129.
52. Pinder SE, Elston CW, Ellis IO. Invasive carcinoma-usual histologic types. In: Elston CW, Ellis IO (eds). The Breast, 3rd edn. Churchill Livingstone: Edinburgh, 1998, pp 283-337.
53. McCarty Jr KS,Woodard BH, Nichols DE,Wilkinson W, McCarty Sr KS. Comparison of biochemical and histochemical techniques for estrogen receptor analyses in mammary carcinoma. Cancer 1980;46: 2842-2845. (Pubitemid 11205645)
54. Elston CW, Ellis IO, Goulding H, et al. Role of pathology in the prognosis and management of breast cancer In: Elston CW, Ellis IO (eds) The Breast. Churchill Livingstone: Edinburgh, 1998, pp 385-433.
55. Grimes M, Coad J, Oliviero B, et al. Comparison of Oncotype DX recurrence score and standard immunohistochemical prognostic markers (abstract). Mod Pathol 2007;20:33A.
56. Wirapati P, Sotiriou C, Kunkel S, et al. Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res 2008; 10:R65.
57. Desmedt C, Haibe-Kains B, Wirapati P, et al. Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes. Clin Cancer Res 2008;14:5158-5165.
58. Yu K, Lee CH, Tan PH, et al. A molecular signature of the Nottingham prognostic index in breast cancer. Cancer Res 2004;64:2962-2968. (Pubitemid 38581389)
59. Lu X, Lu X, Wang ZC, et al. Predicting features of breast cancer with gene expression patterns. Breast Cancer Res Treat 2008;108:191-201. (Pubitemid 351311362)
60. Henson DE, Ries L, Freedman LS, et al. Relationship among outcome, stage of disease, and histologic grade for 22,616 cases of breast cancer. The basis for a prognostic index. Cancer 1991;68:2142-2149.
61. Baehner FL, Watson D, Bollard JT, et al. Gene expression by standardized quantitative RT-PCR in the special histologic subtypes of estrogen receptor positive invasive breast cancer (abstract). Breast Cancer Res Treat 2007;106:S135.
62. Flanagan MB, Dabbs DJ, Brufsky AM, et al. Histopathologic variables predict Oncotype DX recurrence score. Mod Pathol 2008;21:1255-1261.
63. Geradts J, Bean SM, Bentley RC, et al. The oncotype DX recurrence score is correlated with a composite index including routinely reported pathobiologic features. Cancer Invest 2010;28:969-977.
64. Wolf I, Ben-Baruch N, Shapira-Frommer R, et al. Association between standard clinical and pathologic characteristics and the 21-gene recurrence score in breast cancer patients: a population-based study. Cancer 2008;112:731-736. (Pubitemid 351240566)
65. Auerbach J, Kim M, Fineberg S. Can features evaluated in the routine pathologic assessment of lymph node-negative estrogen receptor-positive stage I or II invasive breast cancer be used to predict the Oncotype DX recurrence score? Arch Pathol Lab Med 2010;134:1697-1701.
66. Tang P, Wang J, Hicks DG, et al. A lower Allred score for progesterone receptor is strongly associated with a higher recurrence score of 21-gene assay in breast cancer. Cancer Invest 2010;28:978-982.
67. Liu S, Chia SK, Mehl E, et al. Progesterone receptor is a significant factor associated with clinical outcomes and effect of adjuvant tamoxifen therapy in breast cancer patients. Breast Cancer Res Treat 2010;119:53-61.
68. Arpino G, Weiss H, Lee AV, et al. Estrogen receptorpositive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance. J Natl Cancer Inst 2005;97: 1254-1261. (Pubitemid 41535366)
69. Cui X, Schiff R, Arpino G, et al. Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy. J Clin Oncol 2005;23: 7721-7735. (Pubitemid 46291836)
70. Stendahl M, Ryden L, Nordenskjold B, et al. High progesterone receptor expression correlates to the effect of adjuvant tamoxifen in premenopausal breast cancer patients. Clin Cancer Res 2006;12:4614-4618. (Pubitemid 44297812)
71. Chung LW, Hsieh CL, Law A, et al. New targets for therapy in prostate cancer: modulation of stromalepithelial interactions. Urology 2003;62:44-54. (Pubitemid 37371889)
72. Sung SY, Chung LW. Prostate tumor-stroma interaction: molecular mechanisms and opportunities for therapeutic targeting. Differentiation 2002;70:506-521. (Pubitemid 36194316)
73. Mueller MM, Fusenig NE. Tumor-stroma interactions directing phenotype and progression of epithelial skin tumor cells. Differentiation 2002;70:486-497. (Pubitemid 36194314)
74. Ingber DE. Cancer as a disease of epithelial-mesenchymal interactions and extracellular matrix regulation. Differentiation 2002;70:547-560. (Pubitemid 36194319)